Impact News +++ Worldline Shares Halted After Report of Customer Fraud Cover-Up (Bloomberg) +++ WORLDLINE Aktie -4,57%

ABBISKO Aktie

>ABBISKO Performance

1 Woche: 0%

1 Monat: +15,2%

3 Monate: +15,8%

6 Monate: +115,7%

1 Jahr: +217,9%

laufendes Jahr: +109,5%

>ABBISKO Aktie

Name:

ABBISKO CAYMAN DL-,00001

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG0028A1085 / A3C4Y0

Symbol/ Ticker:

8ZD (Frankfurt)

Kürzel:

FRA:8ZD, ETR:8ZD, 8ZD:GR

Index:

Webseite:

https://www.abbisko.com/

Marktkapitalisierung:

755.99 Mio. EUR

Umsatz:

437.06 Mio. EUR

EBITDA:

-9.36 Mio. EUR

Gewinn je Aktie:

Schulden:

21.06 Mio. EUR

Liquide Mittel:

1743.07 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

227.91 / -

KUV/ KBV/ PEG:

11.75 / 3.08 / -

Gewinnm./ Eigenkapitalr.:

5.62% / 1.44%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

ABBISKO, ABBISKO-B

Letzte Datenerhebung:

25.06.25

>ABBISKO Eigentümer

Aktien: 661.39 Mio. St.

f.h. Aktien: 395.11 Mio. St.

Insider Eigner: 20.58%

Instit. Eigner: 22.48%

Leerverk. Aktien: -

>ABBISKO Peer Group

3SBIO

HBM HOLDINGS

HYGEIA

KEYMED

PARANOVUS

PEIJIA MEDICAL

SHANGHAI HAOHAI

SHANGHAI PHARMACEUTICALS

TONG REN TANG

VIVA BIOTECH

>ABBISKO Chart & Kurs - Stuttgart

>ABBISKO News

16.06.25 - 04:39	Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC (PR Newswire)
	SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular......

10.06.25 - 06:06	Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT (PR Newswire)
	SHANGHAI, June 10, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for pimicotinib, a highly selective, small-molecule CSF-1R inhibitor, as a Class 1......

26.05.25 - 06:16	Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC (PR Newswire)
	SHANGHAI, May 26, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of......

13.05.25 - 05:36	Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress (PR Newswire)
	SHANGHAI, May 12, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the......

28.04.25 - 04:03	2025 AACR \| Abbisko Therapeutics Presents Late-Breaking Pre-clinical Research Results on ABSK112 (EGFR exon20ins), ABSK131 (PRMT5*MTA), and ABK-KRAS-1 (PR Newswire)
	SHANGHAI, April 27, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics 02256.HK) today announced that it has presented four late-breaking pre-clinical research posters at the 2025 AACR conference held in Chicago, Illinois (USA) from April 25 to April 30. Results......

01.04.25 - 05:24	Abbisko Says Merck Exercised Option For Global Rights Of Pimicotinib (AFX)
	KENILWORTH (NJ) (dpa-AFX) - Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of US$85.0 ......

01.04.25 - 02:51	Merck Exercised the Option for the Global Rights of Abbisko Therapeutics′s Pimicotinib (PR Newswire)
	SHANGHAI, March 31, 2025 /PRNewswire/ -- On April 1, 2025, Beijing Time, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fee of USD85.0 million, under the......

28.03.25 - 06:33	Merck übt Option für weltweite Vermarktungsrechte für Pimicotinib aus (Dow Jones)
	DOW JONES--Der Pharma- und Technologiekonzern Merck hat eine Option zur Vermarktung des Wirkstoffkandidaten Pimicotinib von Abbisko Therapeutics in den USA und im Rest der Welt ausgeübt. ......

12.11.24 - 10:13	Merck KGaA: Phase III Trial Of Pimicotinib In Tenosynovial Giant Cell Tumor Meets Primary Endpoint (AFX)
	BERLIN (dpa-AFX) - Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an investigational medicine being developed by Abbisko ......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram